GENOTOXIC ACTION OF AN AQUEOUS EXTRACT OF HELIOTROPIUM-CURASSAVICUM-VAR-ARGENTINUM

被引：14

作者：

CARBALLO, M

MUDRY, MD

LARRIPA, IB

VILLAMIL, E

DAQUINO, M

机构：

[1] UNIV BUENOS AIRES,CATEDRA TOXICOL,DEPT TOXICOL,BUENOS AIRES,ARGENTINA

[2] UNIV BUENOS AIRES,FAC FARM & BIOQUIM,CATEDRA HIG & SALUD,DEPT TOXICOL,BUENOS AIRES,ARGENTINA

[3] NATL ACAD MED BUENOS AIRES,INST INVEST HEMATOL,DEPT GENET,DIV CITOGENET,RA-1450 BUENOS AIRES,DF,ARGENTINA

来源：

MUTATION RESEARCH | 1992年 / 279卷 / 04期

关键词：

MUTAGENESIS; NATURAL PLANTS; HELIOTROPIUM-CURASSAVICUM; MICROSOMAL ACTIVATION;

D O I：

10.1016/0165-1218(92)90240-Z

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Heliotropium curassavicum var. argentinum is widely employed in gout, rheumatism, neuralgias, arteriosclerotic disorders, muscular algias, phlebitis, varix and other illnesses. In order to analyze the genotoxic effect produced in vitro by this medicinal plant, chromosomal aberrations (CA), mitotic index (MI) and anaphase delay (AD) were studied in the CHO cell line, with and without the addition of S9 mix. Prepared according to the Argentine pharmacopeia 0.1, 1, 10 and 100-mu-g/ml plant decoction (aqueous extract) were assayed. One hundred cells per culture were studied for CA and AD, while MI was calculated for 2000 nuclei. The results revealed a significant increase in the percentage of abnormal metaphases (p < 0.001) and in total aberrations (p < 0.001). Both the MI and the AD affected the cell cycle. All results were enhanced by the addition of an S9 fraction. The toxic effect could be associated with pyrrolizidine alkaloids and their N-oxides, which through a process of in vitro metabolism become activated by microsomal oxidation and change into pyrrolic derivatives.

引用

页码：245 / 253

页数：9

共 30 条

[11] PROLIFERATIVE LESIONS IN CHEEK POUCH AND ESOPHAGUS OF HAMSTERS TREATED WITH PLANTS FROM CURACAO, NETHERLAND ANTILLES [J].

DUNHAM, LJ ;

SHEETS, RH ;

MORTON, JF .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1974, 53 (05) :1259-1269

[12]

GARNER RC, 1972, CANCER RES, V32, P2058

[13]

GREEN CR, 1961, BRIT J EXP PATHOL, V42, P369

[14]

HAYASHI Y, 1967, P SOC EXP BIOL MED, V124, P392

[15]

HUXTABLE RJ, 1985, TRENDS PHARMACOL SCI, V1, P299

[16]

LAI Y, 1987, J ENV SCI HLTH C, V5, P121

[17] INVIVO AND INVITRO CYTOGENETIC EFFECTS OF THE ANTI-TUMOR AGENT AMSACRINA (AMSA) [J].

LARRIPA, I ;

DEPARGAMENT, MM ;

DEVINUESA, ML ;

DEMATTEI, A ;

DESALUM, SB .

MUTATION RESEARCH, 1984, 138 (01) :87-91

[18]

LOWRY OH, 1951, J BIOL CHEM, V193, P265

[19]

Matsushima T, 1976, IN VITRO METABOLIC A, P85

[20]

Mattocks A. R., 1972, PHARM FUTURE MAN, V2, P114

← 1 2 3 →